Explore WARF Inventions and Patents
WARF’s portfolio of more than 1,600 patented technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.
Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.
Visit our subscription center to sign up for our monthly email updates and learn when new WARF technologies become available for licensing.
The researchers deleted two genes (Pad1p and Fdc1p) in the yeast that play a role in mediating GVL tolerance. The new strain is the first ethanol-producing yeast specifically tailored for GVL-based techniques.
The system includes units for electro-oxidation, electro-deposition and electro-adsorption. These units work sequentially to (1) break the strong chemical bonds in the waste stream, (2) recover the heavy metal ions and (3) remediate the organic/inorganic material.
A primary advantage of the new system is the redesigned electro-deposition unit, which houses a concentrating cathode and helps in the recovery of metals present even in very low concentrations in a reusable form.
Some of the compounds have been tested in vitro for their ability to increase the secretion of a potent blood sugar hormone in the body called glucagon-like peptide 1 (GLP-1). Others have the ability to selectively inhibit the secretion of interleukin-17 (IL-17), which is essential in many autoimmune diseases including arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.
The synthesis process involves a cascade reaction with transition metal catalysts. The resulting compounds can be further functionalized to yield more substituted indoles.
The compound has been reported as an anticancer drug but was not previously shown to have antimicrobial properties. It was identified by searching for compounds that cause E. coli bacteria to lack a copy of the chromosome following cell division.
The researchers found that a class of compounds called acid sphingomyelinase inhibitors can be used to fight retinal disorders associated with abnormal accumulations of lipofuscin (a cellular waste product), cholesterol or increased inflammation. One such inhibitor, generic name desipramine, is currently sold on the market as an antidepressant. Other acid sphingomyelinase inhibitors also may be suitable.
The method uses a combination of anatomical and functional masking to isolate multiple dispersed lesions from surrounding tissue. In this way, automatic identification tools can target likely tissue on a case-by-case basis, as guided by information about the type of cancer and imaging materials.
First, a patient is administered an imaging agent that identifies tumor tissue. After scanning, a program helps identify and measure the progression of multiple tumor locations based on how and where the agent is taken up. A color-coded output shows measurements at different locations.
The system allows some data accesses via conventional TLB/page table lookups. Other data accesses use a bypass circuit and calculate a physical address, for example, by adding an offset value to the virtual address, rather than performing a lookup. The bypass circuit is able to detect a subset of virtual addresses and translate them to physical addresses according to a stored offset between pairs.
First, calibration factors are obtained using a phantom. The patient or object then is X-rayed to acquire attenuation data at two different energy levels. Images are reconstructed at the different energy levels to produce spatial maps. Based on the calibration factors and spatial maps, a phase contrast image can be produced.